Literature DB >> 28664541

Placebo response and its determinants in children with ADHD across multiple observers and settings: A randomized clinical trial.

Weam Fageera1,2, Alexandru Traicu3, Sarojini M Sengupta1,3, Marie-Eve Fortier1,2, Zia Choudhry1,2, Aurélie Labbe3,4, Natalie Grizenko1,3, Ridha Joober1,2,3.   

Abstract

This study aims to quantify placebo response (PR) in children with attention deficit hyperactivity disorder (ADHD) as assessed by parents and teachers and to explore some of its determinants. Five hundred and forty children with ADHD (ages 6-12) were recruited to a randomized, double-blind, placebo-controlled crossover trial with methylphenidate. The main outcome variable was Conners' Global Index (CGI), based on assessment of behaviour by parents (CGI-P) and teacher (CGI-T). PR was calculated as the difference between CGI-P/T scores at baseline and placebo week. There was a highly significant PR as assessed by the parents' and teachers' (p < 0.001). The magnitude of PR as assessed by parents was greater (10.57 points) compared to that assessed by teachers (3.93 points). The determinants of PR were different between parents and teachers. For parents, income, marital status, education, maternal smoking during pregnancy, and prior psychostimulant exposure (PPE) showed a significant effect on PR. For teachers, only ethnicity and PPE had an effect. The pattern of PR revealed two distinct profiles that may shed some light on the mechanisms involved in PR. PR in children with ADHD varies depending on the setting of the observations and the evaluator. Several psychosocial factors have been identified as modulators of PR. This is relevant for the design and interpretation of clinical trials and for clinical practice.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ADHD; parents; placebo response; predictors; teachers

Mesh:

Substances:

Year:  2017        PMID: 28664541      PMCID: PMC6877247          DOI: 10.1002/mpr.1572

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  45 in total

1.  NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses.

Authors:  D Shaffer; P Fisher; C P Lucas; M K Dulcan; M E Schwab-Stone
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-01       Impact factor: 8.829

Review 2.  Neurobiological mechanisms of the placebo effect.

Authors:  Fabrizio Benedetti; Helen S Mayberg; Tor D Wager; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2005-11-09       Impact factor: 6.167

3.  The placebo effect revisited: lessons learned to date.

Authors:  Irving Kirsch
Journal:  Complement Ther Med       Date:  2013-01-05       Impact factor: 2.446

Review 4.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Eric Mick; Craig Surman; Robert Doyle; Paul Hammerness; Meghan Kotarski; Thomas Spencer
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

Review 6.  Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.

Authors:  Amy F T Arnsten
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

Review 7.  Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment.

Authors:  A Hróbjartsson; P C Gøtzsche
Journal:  J Intern Med       Date:  2004-08       Impact factor: 8.989

8.  Open-label use of placebos in the treatment of ADHD: a pilot study.

Authors:  A D Sandler; J W Bodfish
Journal:  Child Care Health Dev       Date:  2008-01       Impact factor: 2.508

9.  Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway.

Authors:  N D Volkow; G-J Wang; J H Newcorn; S H Kollins; T L Wigal; F Telang; J S Fowler; R Z Goldstein; N Klein; J Logan; C Wong; J M Swanson
Journal:  Mol Psychiatry       Date:  2010-09-21       Impact factor: 15.992

10.  Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.

Authors:  Irving Kirsch; Brett J Deacon; Tania B Huedo-Medina; Alan Scoboria; Thomas J Moore; Blair T Johnson
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  4 in total

1.  Placebo response and its determinants in children with ADHD across multiple observers and settings: A randomized clinical trial.

Authors:  Weam Fageera; Alexandru Traicu; Sarojini M Sengupta; Marie-Eve Fortier; Zia Choudhry; Aurélie Labbe; Natalie Grizenko; Ridha Joober
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-30       Impact factor: 4.035

2.  Neurocognitive, Autonomic, and Mood Effects of Adderall: A Pilot Study of Healthy College Students.

Authors:  Lisa L Weyandt; Tara L White; Bergljot Gyda Gudmundsdottir; Adam Z Nitenson; Emma S Rathkey; Kelvin A De Leon; Stephanie A Bjorn
Journal:  Pharmacy (Basel)       Date:  2018-06-27

3.  Self-management training vs. neurofeedback interventions for attention deficit hyperactivity disorder: Results of a randomized controlled treatment study.

Authors:  Ann-Kathrin Korfmacher; Oliver Hirsch; Mira-Lynn Chavanon; Björn Albrecht; Hanna Christiansen
Journal:  Front Psychiatry       Date:  2022-08-18       Impact factor: 5.435

4.  Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.

Authors:  Stephen V Faraone; Roberto Gomeni; Joseph T Hull; Gregory D Busse; Zare Melyan; Jonathan Rubin; Azmi Nasser
Journal:  Paediatr Drugs       Date:  2021-09-15       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.